Rigel Pharmaceuticals (RIGL) Stock Forecast & Price Target

Rigel Pharmaceuticals is supported by a more diversified commercial profile and a pipeline that is increasingly validated by data, with Gavreto showing compelling RET fusion activity across tumor types, including a 53% ORR in pooled solid tumors, 88% in previously treated pancreatic cancer, and 75% first-line ORR in NSCLC versus 26% on prior standard-of-care therapies. The company’s fundamentals are further strengthened by a sum-of-the-parts framework that assigns about $1.62B of rNPV to Tavalisse, Gavreto, Rezlidhia, and Veppanu, plus roughly $56.1M in net cash, while R289 adds another $3.41/share of clinical NPV based on conservative assumptions. Veppanu’s U.S. launch broadens revenue potential, and Rezlidhia’s real-world and long-term responder data suggest durable benefit in difficult-to-treat AML, reinforcing a positive view on execution, growth, and portfolio durability.

Rigel Pharmaceuticals is facing a bearish fundamental case because its pralsetinib data showed a clear safety disadvantage versus standard of care, with any-grade infections in 71.3% of treated patients and grade ≥3 infections in 28.7% versus 51.9% and 9.6%, respectively. The risk profile is further weakened by 77.8% grade 3-5 adverse events, 6.5% grade ≥3 opportunistic infections, and 8 fatal infection events in 7.4% of pralsetinib-treated patients, while none occurred in the SOC arm. These findings raise meaningful regulatory, commercial, and liability concerns for a company that depends on partnered and pipeline assets to drive value, making execution risk materially higher and the investment outlook negative.